CERO THERAPEUTICS HOLDINGS, INC.

OTC:CEROOTC:CEROW

Biological Products, (No Diagnostic Substances)·SOUTH SAN FRANCISCO, CA

CEO

Ehrlich Christopher B

CFO

Kucharchuk Andrew Albert

Financials

19 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/19/25	→
10-Q	Q2 2025	6/30/25	8/22/25	→
10-Q	Q1 2025	3/31/25	5/15/25	→
10-K/A	FY 2024	12/31/24	4/28/25	→
10-K	FY 2024	12/31/24	4/15/25	→
10-Q/A	Q3 2024	9/30/24	11/20/24	→
↓

Earnings Releases (8-K)

1 shown

Filed	Period
10/11/24	Q3 FY2024	→

News (8-K)

71 shown

Filed	Type	Description
2/13/26	Exec Change	Entry into a Material Definitive Agreement	→
2/4/26	Other	Other Events	→
2/3/26	Delisting	Notice of Delisting or Failure to Satisfy a Continued Listing Rule	→
1/7/26	Reg FD	Regulation FD Disclosure	→
12/19/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/2/25	Agreement	Entry into a Material Definitive Agreement	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
2/20/26	424B3	PROSPECTUS SUPPLEMENT	→
2/4/26	424B3	PROSPECTUS SUPPLEMENT	→
2/3/26	424B3	PROSPECTUS SUPPLEMENT	→
1/8/26	424B3	PROSPECTUS SUPPLEMENT	→
12/19/25	424B3	PROSPECTUS SUPPLEMENT	→
12/5/25	S-1	REGISTRATION STATEMENT	→
↓

Filing History(416 filings)

TypeDateAccessionPeriodSize

424B3

Feb 20, 2026

0001213900-26-018804PROSPECTUS SUPPLEMENT

—

65.7 KB

8-K

Feb 13, 2026

0001213900-26-016474FORM 8-K

Feb 9, 2026

378.3 KB

424B3

Feb 4, 2026

0001213900-26-011847PROSPECTUS SUPPLEMENT

—

37.5 KB

8-K

Feb 4, 2026

0001213900-26-011844CURRENT REPORT

Feb 4, 2026

7.5 MB

424B3

Feb 3, 2026

0001213900-26-011601PROSPECTUS SUPPLEMENT

—

27.3 KB

8-K

Feb 3, 2026

0001213900-26-011587CURRENT REPORT

Jan 29, 2026

227.8 KB

Jan 9, 2026

0001213900-26-002949

Jan 7, 2026

5.3 KB

Jan 9, 2026

0001213900-26-002947

Jan 7, 2026

5.2 KB

Jan 9, 2026

0001213900-26-002945

Jan 7, 2026

5.3 KB

Jan 9, 2026

0001213900-26-002946

Jan 7, 2026

5.3 KB

Jan 9, 2026

0001213900-26-002951

Jan 7, 2026

5.2 KB

Jan 9, 2026

0001213900-26-002952

Jan 7, 2026

5.3 KB

Jan 9, 2026

0001213900-26-002950

Jan 7, 2026

5.3 KB

Jan 9, 2026

0001213900-26-002948

Jan 7, 2026

5.2 KB

424B3

Jan 8, 2026

0001213900-26-002515PROSPECTUS SUPPLEMENT

—

40.8 KB

8-K

Jan 7, 2026

0001213900-26-002187CURRENT REPORT

Jan 7, 2026

11.7 MB

424B3

Dec 19, 2025

0001213900-25-123953PROSPECTUS SUPPLEMENT

—

39.1 KB

8-K

Dec 19, 2025

0001213900-25-123912CURRENT REPORT

Dec 19, 2025

253.5 KB

EFFECT

Dec 11, 2025

9999999995-25-003686

—

1.9 KB

S-1

Dec 5, 2025

0001213900-25-118817REGISTRATION STATEMENT

—

19.3 MB

424B3

Dec 2, 2025

0001213900-25-117357PROSPECTUS SUPPLEMENT

—

47.3 KB

424B3

Dec 2, 2025

0001213900-25-117352PROSPECTUS SUPPLEMENT

—

46.6 KB

DEFA14A

Dec 2, 2025

0001213900-25-117250DEFINITIVE ADDITIONAL MATERIALS

—

28.4 KB

8-K

Dec 2, 2025

0001213900-25-116971CURRENT REPORT

Nov 26, 2025

934.0 KB

DEF 14A

Nov 28, 2025

0001213900-25-115783PROXY STATEMENT

Dec 19, 2025

7.5 MB

25 filings shown

CERO THERAPEUTICS HOLDINGS, INC.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(416 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
12/2/25	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
11/28/25	DEF 14A	DEF 14A	→
11/17/25	PRE 14A	PRE 14A	→
5/7/25	DEF 14A	DEF 14A	→
4/25/25	PRE 14A	PRE 14A	→
10/25/24	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
↓

Filed	Form	Description
1/9/26	4	4	→
1/9/26	4	4	→
1/9/26	4	4	→
1/9/26	4	4	→
1/9/26	4	4	→
1/9/26	4	4	→
↓

Filed	Form	Description
12/11/25	EFFECT	EFFECT	→
8/15/25	EFFECT	EFFECT	→
8/14/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
7/29/25	EFFECT	EFFECT	→
5/29/25	EFFECT	EFFECT	→
5/27/25	POS AM	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1	→
↓